Our products
Obe-cel is currently being investigated in ongoing clinical studies in oncology and autoimmune disease
AUTO1/22 is a novel dual targeting CAR T cell based therapy candidate based on obe-cel. It is designed to combine the enhanced safety, robust expansion & persistence seen with the fast off rate CD19 CAR high sensitivity CD22 CAR to reduce antigen negative relapses. This product candidate is currently in a Phase 1 clinical trial for patients with r/r pediatric ALL.
Autolus is undertaking a Phase 1 study of obe-cel for the treatment of patients with refractory Systemic Lupus Erythematosus (SLE).
The study is designed to evaluate the safety, tolerability and preliminary efficacy of obe-cel for the treatment of SLE.
Autolus believes that the Company's commercial-ready product delivery infrastructure creates a strong foundation for expansion into autoimmune diseases.
AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2 respectively, and both employing a novel and differentiated treatment approach. Each are designed to selectively kill cancerous T cells in a manner that we believe will preserve a portion of the patient’s normal, healthy T cells to maintain immunity.
Since the uses a novel mechanism to target T cells, Autolus has also programmed the product candidate with the RQR8 “safety switch” in order to allow physicians to manage toxicity by eliminating the programmed T cells if a patient experiences severe adverse side effects from the treatment.
AUTO4 is currently being tested in a Phase 1 study in TRBC1-positive peripheral T cell lymphoma.
A programmed T cell therapy targeting GD2 in development for the treatment of both neuroblastoma and other GD2 expressing solid tumors
A Phase 1 clinical trial with AUTO6 was sponsored and conducted by Cancer Research UK, or CRUK, and data demonstrated initial anti-tumor activity in this solid tumor indication.
AUTO6NG builds on preliminary proof of concept data from AUTO6 which incorporates additional cell programming modules to overcome immune suppressive defense mechanisms in the tumor microenvironment, in addition to endowing the CAR T cells with extended persistence capacity. A Phase 1 clinical study is being undertaken, in collaboration with UCL, in children with r/r neuroblastoma. The MAGNETO Phase 1 clinical trial of AUTO6NG in r/r neuroblastoma was initiated in December 2023.
AUTO8 is our next-generation product candidate for multiple myeloma which comprises two independent CARs for the multiple myeloma targets, BCMA and CD19. We have developed an optimized BCMA CAR which is designed for improved killing of target cell that express BCMA at low levels. This has been combined with fast off rate CD19 CAR from obe-cel.
We believe that the design of AUTO8 has the potential to induce deep and durable responses and extend the durability of effect over other BCMA CARs currently in development.
In collaboration with UCL, the Company initiated a study in Q1 2022 and data presented at ASH in December 2023 demonstrated that AUTO8 was well tolerated, with responses observed in all patients.